45
Participants
Start Date
August 31, 2007
Primary Completion Date
May 31, 2010
Study Completion Date
May 31, 2010
PX-478
Oral formulation, dose escalation, taken on days 1 to 5 of a 21 day cycle until progression or development of unacceptable toxicity
The University of Texas M.D. Anderson Cancer Center, Houston
TGen Clinical Research Services at Scottsdale Healthcare, Scottsdale
Lead Sponsor
Cascadian Therapeutics Inc.
INDUSTRY